Sham
VC Fund
Lyon, France
Sham is a mutual insurance company that provides medical malpractice insurance in France.
- Total investments:
- 18
- Last investment:
- Lead investor:
- 17%
Last updated:
For AI agents: llms.txt
Industries Sham invests in
Stages Sham invests in
Countries Sham invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $6.1M–$74M
- Series B
- $3.3M–$80M
- Venture - Series Unknown
- $1.8M–$12M
Investment Focus
Industry
- Medical Device 9 (50%)
- Biotechnology 8 (44%)
- Health Care 7 (39%)
- Medical 5 (28%)
- Pharmaceutical 3 (17%)
Stage
- Series B 8 (44%)
- Series A 3 (17%)
- Venture - Series Unknown 3 (17%)
- Seed 2 (11%)
- Series C 1 (6%)
Country
- France 14 (78%)
- United States 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Ramon Maluenda
Operations manager
|
Operations manager | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Therapixel develops and commercializes AI-based software for breast cancer detection and characterization | $15.6M / Series B / May 12, 2022 | ||
| Germitec is a healthcare company that designs, Commercialize UV-C disinfection systems for hospital hygiene system. | $11.6M / Venture - Series Unknown / May 10, 2022 | ||
| Cairdac is a manufacturer of autonomous leadless pacing transcatheter system capable of powering the device with no battery-life limitation. | $18.8M / Series A / Mar 31, 2022 | ||
| Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism. | $80M / Series B / Sep 16, 2021 | ||
| Keenturtle is a medtech that provides e-health solutions to enhance medical & economic field such as provision of health data. | $1.8M / Venture - Series Unknown / Aug 02, 2021 | ||
| Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases. | $38.9M / Series B / Jul 21, 2021 | ||
| Mablink Bioscience is a biotechnology company specialized in the development of a new class of cancer drugs, called Antibody Drug Conjugate (ADC). | $4.8M / Seed / Apr 27, 2021 | ||
| AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance. | $2.9M / Seed / Nov 04, 2020 | ||
| CyberMDX is an IOT security leader dedicated to protecting the quality care of health delivery worldwide. CyberMDX provides cloud-based cybersecurity solutions that support the advancement of The Internet of Medical Things. The CyberMDX solution identifies endpoints and assesses vulnerabilities to detect, respond to, and prevent cyber incidents.Deployed worldwide, CyberMDX is designed to integrate with our customers' existing environments through its scalable, easy-to-deploy and agentless solution. | $20M / Series B / Apr 07, 2020 | ||
| Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism. | $74.2M / Series A / Jul 31, 2019 | ||
| See all 18 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Sham invest in?
Sham invests primarily in Medical Device, Biotechnology and Health Care startups, most often at Series B and Series A stage. Most of the 18 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Sham's check size?
Sham typically joins rounds of $6.1M–$74M at Series A, $3.3M–$80M at Series B and $1.8M–$12M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Sham participates in.
How do I contact Sham?
Public channels for Sham include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Sham?
The team at Sham includes Ramon Maluenda (Operations manager). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
